Keryx Biopharma (KERX) Reports Strong Phase 2 Data for Perifosine w/ Sorafenib in Certain HL Patients
Go back to Keryx Biopharma (KERX) Reports Strong Phase 2 Data for Perifosine w/ Sorafenib in Certain HL Patients| AETERNA ZENTARIS (NASDAQ: AEZS) | Delayed: 5.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.72 | 52 Week High | $15.70 | |||
| Open | $5.72 | 52 Week Low | $0.04 | |||
| Day High | $5.72 | P/E | N/A | |||
| Day Low | $5.72 | EPS | $0.00 | |||
| Volume | 3 | |||||
| Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) | Delayed: 3.36 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.36 | 52 Week High | $7.80 | |||
| Open | $438.10 | 52 Week Low | $2.80 | |||
| Day High | $3.36 | P/E | N/A | |||
| Day Low | $3.36 | EPS | $-0.45 | |||
| Volume | 1,132,646 | |||||
